|Bid||90.50 x N/A|
|Ask||92.00 x N/A|
|Day's Range||92.00 - 96.00|
|52 Week Range||34.40 - 136.20|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2023 - Mar 03, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for 26M.BE
Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced a late-breaking presentation of concurrent combination results of adagrasib and pembrolizumab in first line advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Findings will be presented on December 7 at the 2022 European Society of Medical Oncology Immuno-Oncology (ESMO IO) Annual Congress as an oral presentation from 2:15 p.m.-2:25 p.m. CET / 8:15 a.m.-8:25 a.m
Mirati Therapeutics' (MRTX) new drug application (NDA), seeking approval for adagrasib, its KRAS inhibitor drug, for previously-treated KRASG12C-mutated NSCLC is under review with the FDA with a decision expected by Dec 14.
Big Pharma suitors could be looking to buy Mirati Therapeutics, according to reports that sent MRTX stock close to a breakout Wednesday.